CollabRx Announces Receipt of NASDAQ Notice of Non-Compliance With Rule 5550(b)(1)
GlobeNewswire - Wed Dec 03, 3:01PM CST
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company"
CLRX: 0.65 (-0.06)
CollabRx Announces Receipt of NASDAQ Notice of Bid Price Deficiency
GlobeNewswire - Mon Nov 24, 6:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company"
CLRX: 0.65 (-0.06)
CollabRx EPS of -$0.35
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:28PM CST
CLRX: 0.65 (-0.06)
CollabRx Reports Second Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Thu Nov 13, 3:00PM CST
CollabRx, Inc. (the "Company"
CLRX: 0.65 (-0.06)
CollabRx and Cartagenia Partner in Interpretation Support and Reporting of Genetic Sequencing-Based Tests for Cancer
PRWeb - Mon Nov 10, 8:04AM CST
CollabRx, Inc. (NASDAQ: CLRX) today announced a partnership with Cartagenia, Inc. to provide and promote to the clinical laboratory market an end-to-end software solution to support clinicians and pathologists with clinical genetic testing and reporting in oncology, including next-generation sequencing (NGS) -based tests. Cartagenia is a leader in providing genetics labs and clinicians with software-based workflow support for variant assessment support, lab reporting, and integration of clinical knowledge-bases. Combined with CollabRx's industry-leading decision support solutions in oncology, the partnership will enable clinical and pathology laboratories to generate automated workflows allowing them to quickly and efficiently analyze and report on NGS test results in cancer by providing integrated access to CollabRx's highly credible medical and scientific knowledge with their own proprietary information to create physician- ready reports.
CLRX: 0.65 (-0.06)
Cartagenia Partners with CollabRx to Provide Pathology Laboratories and Cancer Centers Access to Personalized Information on Therapeutic Options
PR Newswire - Mon Nov 10, 8:00AM CST
Cartagenia, leader in providing genetic labs and clinicians with software-based workflow support for variant assessment, lab reporting, and access of relevant knowledge-bases, today announced a partnership with CollabRx that will provide Cartagenia's customers access to CollabRx's industry-leading treatment information resources and services.
CLRX: 0.65 (-0.06)
CollabRx and Collaborators at Leading Academic Centers Publish Clinical Decision Support Model for Precision Oncology
PRWeb - Wed Nov 05, 8:11AM CST
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of clinical decision support solutions in oncology, today announced the publication of a clinical decision support model for oncology as an advance publication in the current online edition of the open-access journal Oncoscience.1 The publication titled "A framework for genomic biomarker actionability and its use in clinical decision making" was co-authored by senior members of CollabRx's scientific team in collaboration with clinical researchers and physicians at the University of California, San Diego, the University of Texas MD Anderson Cancer Center, the Huntsman Cancer Institute, Banner MD Anderson Cancer Center, and the Vall d'Hebron Institut d'Oncologia, Universitat Autonoma of Barcelona.
CLRX: 0.65 (-0.06)
CollabRx Editor-in-Chief & CMO George D. Lundberg, MD Wins 2014 ASCP Ward Burdick Award for Distinguished Service to Pathology
GlobeNewswire - Fri Oct 17, 8:17AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq:CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, announced that George D. Lundberg, MD, the Company's editor-in-chief, chief medical officer and chair of its Editorial Advisory Board, has won the 2014 Ward Burdick Award for Distinguished Service to Pathology from the Board of Directors of the American Society for Clinical Pathology (ASCP). Dr. Lundberg was presented with his award during the ASCP Annual Meeting in Tampa, Florida on October 9.
CLRX: 0.65 (-0.06)
CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data
PRWeb - Tue Sep 16, 5:22AM CDT
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, launched its expanded Genetic Variant Annotation™ (GVA™) Service that now supports the interpretation of copy number variation (CNV) data in cancer, resulting in a single, user-friendly report that contains clinically relevant and dynamically updated information that has been used toward cancer treatment planning and support of clinical research. CNVs, which involve both duplications and deletions of the human genome, have been increasingly recognized as playing a role in certain diseases, including cancer.
CLRX: 0.65 (-0.06), AFFX: 8.94 (-0.36)
CollabRx Reports First Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Thu Aug 14, 3:00PM CDT
CollabRx, Inc. (the "Company"
CLRX: 0.65 (-0.06)
CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update
GlobeNewswire - Thu Jul 31, 8:32AM CDT
via PRWEB - CollabRx, Inc. (NASDAQ: CLRX), a leading provider of expert systems that inform therapeutic decision-making in oncology, today announced that it will hold an investor conference call on August 14, 2014 to discuss the Company's financial results for the first quarter of fiscal 2015 and to provide an update about the business in the current fiscal year.
CLRX: 0.65 (-0.06)
CollabRx and OncoSolutions Cancer Center Partner To Provide Precision Oncology Services
PRWeb - Tue Jul 01, 4:34AM CDT
CollabRx, Inc. (NASDAQ: CLRX), a data analytics company and leading provider of expert systems that inform therapeutic decision-making in oncology, and OncoSolutions Cancer Center, a private oncology company based in Singapore, announce a multiyear agreement. CollabRx will provide its Genetic Variant Annotation (GVA) Service™ to oncologists at OncoSolutions so they can quickly and efficiently glean insight from a patient's tumor genetic profile to determine a treatment plan. This "precision medicine" approach to treatment planning is key to evaluating all possible therapy options to provide the best possible patient care and optimize clinical outcomes.
CLRX: 0.65 (-0.06)